.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,637,320

« Back to Dashboard

Summary for Patent: 5,637,320

Title: Controlled absorption naproxen formulation for once-daily administration
Abstract:A once-daily naproxen formulation for oral administration having a first portion of the naproxen as a multi-particulate pellet form, each pellet having a core of naproxen or a pharmaceutically acceptable salt thereof in association with an organic acid, the core being surrounded by a multi-layer membrane and optionally a second portion of naproxen formulated to release the drug promptly following oral administration.
Inventor(s): Bourke; Edward A. (Athlone, IE), Mulligan; Seamus (Athlone, IE)
Assignee: Elan Corporation, PLC (Athlone, IE)
Application Number:08/227,566
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Device;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,637,320

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland149/90Jan 15, 1990

International Patent Family for Patent: 5,637,320

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria126055<disabled in preview>
Australia639519<disabled in preview>
Australia6933291<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc